Alternative splicing is a crucial mechanism of gene regulation that enables condition- and tissue-specific expression of gene isoforms. Its dysregulation plays a role in various diseases such as cancer, neurological disorders, and metabolic conditions. Despite its importance, accurate detection of alternative splicing events remains challenging. Comprehensive alternative splicing event detection typically requires deep sequencing with over 100 million reads; however, much of the publicly accessible RNA sequencing data is of lower sequencing depth. Recent advances, particularly deep learning models working with genomic sequences, offer new avenues for predicting alternative splicing without reliance on high sequencing depth data. Our study addresses the question: Can we utilize the vast repository of publicly available RNA sequencing data for comprehensive alternative splicing detection, despite the low sequencing depth? Our results demonstrate the potential of sequence-based deep learning tools such as AlphaGenome, SpliceAI and DeepSplice for initial hypothesis development and as additional filters in standard RNA sequencing pipelines, especially when sequencing depth is limited. Nonetheless, validation with higher sequencing depths remains essential for confirmation of splice events. Overall, our findings underscore the need for integrative methods combining genomic sequence data and RNA sequencing data for the prediction of tissue- and condition-specific alternative splicing in resource-limited settings.

SUMMARY: Proteome studies frequently encounter challenges in down-stream data analysis due to limited bioinformatics resources, rapid data generation, and variations in analytical methods. To address these issues, we developed SpectroPipeR, an R package designed to streamline data analysis tasks and provide a comprehensive, standardized pipeline for Spectronaut® DIA-MS data. This novel package automates various analytical processes, including XIC plots, ID rate summary, normalization, batch and covariate adjustment, relative protein quantification, multivariate analysis, and statistical analysis, while generating interactive HTML reports for e.g. ELN systems. AVAILABILITY AND IMPLEMENTATION: The SpectroPipeR package (manual: https://stemicha.github.io/SpectroPipeR/) was written in R and is freely available on GitHub (https://github.com/stemicha/SpectroPipeR).

SUMMARY: A plethora of tools exist for RNA-Seq data analysis with a focus on alternative splicing (AS). However, appropriate data for their comparative evaluation is missing. The R package ASimulatoR simulates gold standard RNA-Seq datasets with fine-grained control over the distribution of AS events, which allow for evaluating alternative splicing tools, e.g. to study the effect of sequencing depth on the performance of AS event detection. AVAILABILITY AND IMPLEMENTATION: ASimulatoR is freely available at https://github.com/biomedbigdata/ASimulatoR as an R package under GPL-3 license.

In this work, we introduce an entirely data-driven and automated approach to reveal disease-associated biomarker and risk factor networks from heterogeneous and high-dimensional healthcare data. Our workflow is based on Bayesian networks, which are a popular tool for analyzing the interplay of biomarkers. Usually, data require extensive manual preprocessing and dimension reduction to allow for effective learning of Bayesian networks. For heterogeneous data, this preprocessing is hard to automatize and typically requires domain-specific prior knowledge. We here combine Bayesian network learning with hierarchical variable clustering in order to detect groups of similar features and learn interactions between them entirely automated. We present an optimization algorithm for the adaptive refinement of such group Bayesian networks to account for a specific target variable, like a disease. The combination of Bayesian networks, clustering, and refinement yields low-dimensional but disease-specific interaction networks. These networks provide easily interpretable, yet accurate models of biomarker interdependencies. We test our method extensively on simulated data, as well as on data from the Study of Health in Pomerania (SHIP-TREND), and demonstrate its effectiveness using non-alcoholic fatty liver disease and hypertension as examples. We show that the group network models outperform available biomarker scores, while at the same time, they provide an easily interpretable interaction network.